UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Latecomer experimental drug no better than Dupixent in trial
Pharmaceutical firms have strived to make latecomer drugs to beat Dupixent ...
by Kim Yun-mi
|
2019-06-24 15:49
라인
Off-label use of Mabthera Inj. denied
The Health Insurance Review and Assessment Service (HIRA) said it has disap...
by Kim Yun-mi
|
2019-06-20 15:49
라인
‘Korean cancer researchers have risen to world-class level’
The Korean Cancer Study Group (KCSG) said Korean institutions and researche...
by Kim Yun-mi
|
2019-06-20 15:04
라인
‘Immunotherapies contributed to advancement of neoadjuvant cancer treatment’
Immunotherapies, less toxic than conventional cytotoxic chemotherapies, hav...
by Kim Yun-mi
|
2019-06-19 15:36
라인
AstraZeneca to invest $630 million in Korean biohealth sector
AstraZeneca said it would invest $630 million into Korea’s biotech and heal...
by Kim Yun-mi
|
2019-06-17 11:33
라인
‘Moon administration to expand investment into healthcare, quality of life’
The Moon Jae-in government will enhance the social safety net, build a life...
by Kim Yun-mi
|
2019-06-14 16:49
라인
Atopic dermatitis patients demand reimbursement for Sanofi’s biological drug
Korean patients with severe atopic dermatitis gathered in front of the Nati...
by Kim Yun-mi
|
2019-06-12 13:29
라인
Forxiga prevents kidney disease in diabetes patients
AstraZeneca’s sodium-glucose cotransporter-2 (SGLT2) inhibitor Forxiga (ing...
by Kim Yun-mi
|
2019-06-11 15:40
라인
HIV prevention pill to get insurance benefit in Korea
The local medical community is likely to use a drug to prevent HIV infectio...
by Kim Yun-mi
|
2019-05-30 13:25
라인
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy
Oncology researchers around the world are paying keen attention to MDM2 (mo...
by Kim Yun-mi
|
2019-05-29 12:35
라인
‘Enstilum treats all psoriasis from mild to severe ones’
Enstilum Foam (betamethasone dipropionate/calcipotriol), a foam-type treatm...
by Kim Yun-mi
|
2019-05-28 14:44
라인
‘Risk-sharing agreements back up economic feasibility review’
An expert said expanding risk-sharing agreements (RSA) and introducing a po...
by Kim Yun-mi
|
2019-05-22 14:46
라인
Japan issued safety warning on Lilly’s breast cancer drug. Will Korea, too?
Japan’s Health Ministry warned that Eli Lilly’s breast cancer therapy Verze...
by Kim Yun-mi
|
2019-05-21 14:19
라인
Low-income, single women more vulnerable to osteoporosis
Women who are living by herself, earning low incomes, and having poor knowl...
by Kim Yun-mi
|
2019-05-20 15:40
라인
Latecomer SGLT2 inhibitor Steglatro unlikely to get free ride
The Korean Diabetes Association (KDA)’s revised guideline for diabetes trea...
by Kim Yun-mi
|
2019-05-15 15:30
라인
Keytruda wins nod as adjuvant therapy after melanoma surgery
The Ministry of Food and Drug Safety has approved PD-1 inhibitor immunother...
by Kim Yun-mi
|
2019-05-15 14:14
라인
Antibody-drug conjugates on the rise as Herceptin’s patent to expire soon
With Roche’s HER2-positive breast cancer drug Herceptin (trastuzumab) facin...
by Kim Yun-mi
|
2019-05-13 14:23
라인
Xeljianz is easier to use than biologic therapies -- is it safer, however?
Pfizer’s Xeljianz (tofacitinib), an oral Janus kinase (JAK) inhibitor to tr...
by Kim Yun-mi
|
2019-05-10 15:34
라인
[Exclusive] MSD Korea playing tricks to reduce daycare cost
Korea Biomedical Review ran an exclusive story on an executive at MSD Korea...
by Kim Yun-mi
|
2019-05-09 11:20
라인
[Reporter’s Notebook] Roche agreed, MSD and BMS should, too
Immunotherapies have become so effective and popular that some cancer patie...
by Kim Yun-mi
|
2019-05-07 14:30
-
이전
11
12
13
14
15
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top